Alsonex
Alsonex is a biopharmaceutical company focused on developing new treatments for neurodegenerative diseases, including Motor Neuron Disease, Parkinson's, Alzheimer's, and Huntington's disease. Founded in 2014, it aims to advance products through proof-of-concept stages and collaborate with larger pharmaceutical companies for further development. The company's lead project is ALS-205, which has completed Phase I and Phase Ib clinical trials, demonstrating safety and target engagement. Alsonex's mission is to discover and develop new pharmaceutical products to address the urgent clinical needs in neurodegenerative diseases, leveraging research into neuroinflammation and the innate immune system.
Industries
Nr. of Employees
small (1-50)
Products
Orally active small-molecule C5a1 receptor antagonist (lead candidate)
A small-molecule antagonist selective for the C5a1 receptor that is chemically stable in biological fluids, orally active at low doses in vivo, demonstrates brain penetration, and has shown preclinical efficacy in transgenic ALS models; progressed through Phase I single- and multiple-ascending dose studies and a Phase Ib study demonstrating target engagement in patients; granted orphan designation by US and European regulators.
Orally active small-molecule C5a1 receptor antagonist (lead candidate)
A small-molecule antagonist selective for the C5a1 receptor that is chemically stable in biological fluids, orally active at low doses in vivo, demonstrates brain penetration, and has shown preclinical efficacy in transgenic ALS models; progressed through Phase I single- and multiple-ascending dose studies and a Phase Ib study demonstrating target engagement in patients; granted orphan designation by US and European regulators.
Services
Advancement of candidate therapeutics through first-in-human and early patient studies to achieve proof-of-concept, followed by partnering or licensing for later-stage development.
Advancement of candidate therapeutics through first-in-human and early patient studies to achieve proof-of-concept, followed by partnering or licensing for later-stage development.
Expertise Areas
- Neurodegenerative disease drug development
- Complement-targeted therapeutics
- Small-molecule medicinal chemistry
- Preclinical translational neuroscience
Key Technologies
- Small-molecule receptor antagonists
- Complement system modulation (C5a/C5a1 targeting)
- Transgenic rodent disease models (SOD1G93A)
- Oral CNS drug development and BBB penetration assessment